Antigen ID	TAR0UYFIF
Antigen Name	Epidermal growth factor receptor (EGFR)
Gene Name	EGFR
Gene ID	1956
Synonym	ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1;Receptor tyrosine-protein kinase erbB-1
Sequence	MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV APQSSEFIGA     Click to Show/Hide
Family	Tyr protein family
Function	Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin- binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration. Plays a role in enhancing learning and memory performance. Plays a role in mammalian pain signaling (long-lasting hypersensitivity).     Click to Show/Hide
Uniprot Entry	EGFR_HUMAN
HGNC ID	HGNC:3236
KEGG ID	hsa:1956

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	1711 (scFv)-SNAP-AuriF	Auristatin F	Microtubule (MT)	BG based linker	[1]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	P1-528mAb	Undisclosed	Undisclosed	Undisclosed	[2]
ADC Info	P2-528mAb	Undisclosed	Undisclosed	Undisclosed	[2]
ADC Info	P3-528mAb	Undisclosed	Undisclosed	Undisclosed	[2]
ADC Info	37218930 2P3-528mAb	Undisclosed	Undisclosed	Undisclosed	[2]
ADC Info	CoP-528mAb	Undisclosed	Undisclosed	Undisclosed	[2]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	WO2024105205A1 2g-981	KSPI6-1	Undisclosed	Undisclosed	[3]
ADC Info	WO2024105205A1 3g-981	KSPI6-1	Undisclosed	Undisclosed	[3]
ADC Info	WO2024105205A1 4g-981	KSPI6-1	Undisclosed	Undisclosed	[3]
ADC Info	WO2024105205A1 5g-981	KSPI6-1	Undisclosed	Undisclosed	[3]
ADC Info	WO2024105205A1 6g-981	KSPI6-1	Undisclosed	Undisclosed	[3]
ADC Info	WO2024105205A1 7g-981	KSPI6-1	Undisclosed	Undisclosed	[3]
ADC Info	WO2024105205A1 8g-981	KSPI6-1	Undisclosed	Undisclosed	[3]
ADC Info	WO2024105205A1 14g-981	KSPI6-1	Undisclosed	Undisclosed	[3]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	S7 ADC	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[4]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	S7-E430G ADC	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[4]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	AbA-vcMMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[5]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Ab1-mcMMAF	Monomethyl auristatin F	Microtubule (MT)	Maleimido-caproyl	[6]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Ab3-mcMMAF	Monomethyl auristatin F	Microtubule (MT)	Maleimido-caproyl	[6]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	AbA-vcMMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[6]
ADC Info	AbA-mcMMAE	Monomethyl auristatin E	Microtubule (MT)	Maleimido-caproyl	[6]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	SYS6010	JS-1	DNA topoisomerase 1 (TOP1)	Mc-Gly-Gly-Phe-Gly
ADC Info	BB-1705	Eribulin	Microtubule (MT)	Mal-PEG2-Val-Cit-PABC
ADC Info	ABBV-637	BCL-xL inhibitor	Bcl-2-like protein 1 (BCL2L1)	Undisclosed
ADC Info	ALX2004	TOP1 inhibitor	DNA topoisomerase 1 (TOP1)	Undisclosed
ADC Info	HMPL-A580	HM5041609	PI3K; PIKK	A cleavable linker

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	HuFc-MMAE	Monomethyl auristatin E	Microtubule (MT)	Gly3-Val-Cit-PABC	[7]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	HLX42	TOP1 inhibitor	DNA topoisomerase 1 (TOP1)	A cleavable linker

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Anti-hEGFR (IgG4)-ABNO-DM-1: E4-AD	Mertansine DM1	Microtubule (MT)	ABNO Linker	[8]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Anti-EGFR-Sulfo-SMCC-DM1	Mertansine DM1	Microtubule (MT)	Sulfo-SMCC	[9]
ADC Info	Anti-EGFR-Ala-Ala-IGN	Indolinobenzodiazepine dimer	Human Deoxyribonucleic acid (hDNA)	Ala-Ala dipeptide	[10]
ADC Info	Anti-EGFR-Val-Gln-IGN	Indolinobenzodiazepine dimer	Human Deoxyribonucleic acid (hDNA)	Val-Gln dipeptide linker	[10]
ADC Info	EGFR-ADC 13a	PBD dimer 14a	Human Deoxyribonucleic acid (hDNA)	Adipic acid-Val-Ala-PABC	[11]
ADC Info	EGFR-ADC 13b	PBD dimer 14b	Human Deoxyribonucleic acid (hDNA)	Adipic acid-Val-Ala-PABC	[11]
ADC Info	EGFR-ADC 13c	PBD dimer 14c	Human Deoxyribonucleic acid (hDNA)	Adipic acid-Val-Ala-PABC	[11]
ADC Info	WO2023124537A1+ADC1	Active metabolite of irinotecan SN38	DNA topoisomerase 1 (TOP1)	DBCO-VC-PAB	[12]
ADC Info	WO2023124537A1+ADC2	Active metabolite of irinotecan SN38	DNA topoisomerase 1 (TOP1)	DBCO-VC-PAB	[12]
ADC Info	WO2023124537A1+ADC3	Active metabolite of irinotecan SN38	DNA topoisomerase 1 (TOP1)	DBCO-VC-PAB	[12]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	40H3-Tesirine	SG3199	Human Deoxyribonucleic acid (hDNA)	Mal-PEG8-Val-Ala-PABC	[13]
ADC Info	40H3-MCVCPAB-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[13]
ADC Info	40H3-CL2A-SN38	Active metabolite of irinotecan SN38	DNA topoisomerase 1 (TOP1)	CL2A	[13]
ADC Info	40H3-SMCC-DM1	Mertansine DM1	Microtubule (MT)	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[13]
ADC Info	40H3-Deruxtecan	DX-8951 derivative (DXd)	DNA topoisomerase 1 (TOP1)	Mc-Gly-Gly-Phe-Gly	[13]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	SHR-A1307	SHR152852	Microtubule (MT)	L2-MC	[14]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	LA22-MMC	Mitomycin C	Human Deoxyribonucleic acid (hDNA)	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[15]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Anti-EGFR-PEG4-Mal-DM1	Mertansine DM1	Microtubule (MT)	PEG4-Mal	[16]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	US20220378928A1 C-11	US20220378928A1 C-11 Payload	Undisclosed	US20220378928A1 C-11 Linker	[17]
ADC Info	US20220378928A1 C-20	US20220378928A1 C-11 Payload	Undisclosed	US20220378928A1 C-20 Linker	[17]
ADC Info	US20220378928A1 C-21	US20220378928A1 C-11 Payload	Undisclosed	US20220378928A1 C-21 Linker	[17]
ADC Info	US20220378928A1 C-23	US20220378928A1 C-11 Payload	Undisclosed	US20220378928A1 C-23 Linker	[17]
ADC Info	US20220378928A1 C-24	US20220378928A1 C-11 Payload	Undisclosed	US20220378928A1 C-24 Linker	[17]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	MYK-3	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[18]
ADC Info	BA03-MC-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[18]
ADC Info	BA03-MCC-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[18]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Becotatug vedotin	MMAE	Microtubule (MT)	Mc-Val-Cit-PABC

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	C4-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[19]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Cet-4S-2M	CN108853514B-Cet-4S-2M-payload	Undisclosed	CN108853514B-Cet-4S-2M-linker	[20]
ADC Info	Cet-8E	CN108853514B-Cet-8E-payload	Undisclosed	CN108853514B-Cet-8E-linker	[20]
ADC Info	Cet-8S-4M	Undisclosed	Undisclosed	Undisclosed	[20]
ADC Info	Cet-4M	Undisclosed	Undisclosed	Undisclosed	[20]
ADC Info	Cet-8E-2M	Undisclosed	Undisclosed	Undisclosed	[20]
ADC Info	Cet-8s	Undisclosed	Undisclosed	Undisclosed	[20]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Cetux Cys-vc-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[21]
ADC Info	Cetuximab- (FGX16-11)	FGX8-46	Human Deoxyribonucleic acid (hDNA)	Mc-Val-Ala-PABC	[22]
ADC Info	Hu-Alpha-EGFR-172	IMSA172	Stimulator of interferon genes protein (STING1)	Mc-Val-Cit-PABC	[23]
ADC Info	C-IgG-Val-Cit-MMAE	Monomethyl auristatin E	Microtubule (MT)	Gly3-Val-Cit-PABC	[7]
ADC Info	Cetuximab-Puromycin	Puromycin	Ribosome (RB)	Succinimidyl acetylthiopropionate (SATP)	[24]
ADC Info	Cet-DM1	Mertansine DM1	Microtubule (MT)	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[25]
ADC Info	MAb-DMBA-SIL-MMAE	Monomethyl auristatin E	Microtubule (MT)	DMBA-SIL	[26]
ADC Info	Cet-ZA ADC	Zoledronic acid	Geranylgeranyl pyrophosphate synthase (GGPS1)	Undisclosed	[27]
ADC Info	MAb-DMBA-SIL-Dox	Doxorubicin	DNA topoisomerase 2-alpha (TOP2A)	DMBA-SIL	[26]
ADC Info	Cetuximab-Val-Cit-Dox	Doxorubicin	DNA topoisomerase 2-alpha (TOP2A)	Mc-Val-Cit-PABC	[28]
ADC Info	Erbitux-MHT-71	Auristatin F	Microtubule (MT)	MHT-71	[29]
ADC Info	Quinoin cetuximab immunoconjugate	Quinoin	Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[30]
ADC Info	ITcetuximab	Saporin	Microtubule (MT)	Undisclosed	[31]
ADC Info	Cet-TPL	Triptolide	Nuclear factor NF-kappa-B p105 subunit (NFKB1)	N-hydroxysuccinimide based linker	[32]
ADC Info	Cetuximab-DNA conjugate	DNA mimics	Human Deoxyribonucleic acid (hDNA)	Undisclosed	[33]
ADC Info	EGFR-ADC-07 (DAR8)	EGFR-ADC-07(DAR8) payload	Undisclosed	EGFR-ADC-07(DAR8) linker	[34]
ADC Info	EGFR-ADC-07 (DAR4)	EGFR-ADC-07(DAR4) payload	Undisclosed	EGFR-ADC-07(DAR4) linker	[34]
ADC Info	EGFR-ADC-08 (DAR8)	EGFR-ADC-08(DAR8) payload	Undisclosed	EGFR-ADC-08(DAR8) linker	[34]
ADC Info	EGFR-ADC-08 (DAR4)	EGFR-ADC-08(DAR4) payload	Undisclosed	EGFR-ADC-08(DAR4) linker	[34]
ADC Info	EGFR-ADC-32 (DAR4)	EGFR-ADC-32(DAR4) payload	Undisclosed	EGFR-ADC-32(DAR4) linker	[34]
ADC Info	Cetuximab-Comound (Ia)	NeoDegrader P1	Protein cereblon (CRBN)	Cetuximab-Comound (Ia) linker	[35]
ADC Info	WO2017089895A1 ADC64	Monomethyl auristatin F	Microtubule (MT)	WO2017089895A1_ADC64 linker	[36]
ADC Info	WO2017089895A1 ADC65	Monomethyl auristatin E	Microtubule (MT)	WO2017089895A1_ADC65 linker	[36]
ADC Info	WO2017089895A1 ADC66	Monomethyl auristatin F	Microtubule (MT)	WO2017089895A1_ADC66 linker	[36]
ADC Info	WO2022078260A1 ADC-9	Ln-D2	DNA topoisomerase 1 (TOP1)	WO2022078260A1_ADC-9 linker	[37]
ADC Info	WO2022078260A1 ADC-10	Ln-D7	DNA topoisomerase 1 (TOP1)	WO2022078260A1_ADC-10 linker	[37]
ADC Info	EGFR-MMAU ADC	Glucuronyl-monomethyl-auristatin E (MMAU)	Microtubule (MT)	Mc-Val-Cit-PABC	[38]
ADC Info	Cetuximab-vc-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[39]
ADC Info	CTX-MMAE	Monomethyl auristatin E	Microtubule (MT)	PD-Val-Cit-PABC	[40]
ADC Info	EGFR ADC-21	Monomethyl auristatin E	Microtubule (MT)	Vinylsulfonamide based linker 15	[41]
ADC Info	EGFR ADC-22	Monomethyl auristatin E	Microtubule (MT)	Vinylsulfonamide based linker 16	[41]
ADC Info	EGFR ADC-23	Monomethyl auristatin E	Microtubule (MT)	Vinylsulfonamide based linker 17	[41]
ADC Info	WO2017089890A1 ADC64	Monomethyl auristatin F	Microtubule (MT)	WO2017089890A1_ADC64 linker	[42]
ADC Info	WO2017089890A1 ADC65	Monomethyl auristatin E	Microtubule (MT)	WO2017089890A1_ADC65 linker	[42]
ADC Info	WO2017089890A1 ADC66	Monomethyl auristatin F	Microtubule (MT)	WO2017089890A1_ADC66 linker	[42]
ADC Info	Cetuximab-Compound 9	Mertansine DM1	Microtubule (MT)	Cetuximab-Compound 9 linker	[43]
ADC Info	Cetuximab-Compound 17	Mertansine DM4	Microtubule (MT)	Cetuximab-Compound 17 linker	[43]
ADC Info	Cetuximab-Compound 25	Monomethyl auristatin E	Microtubule (MT)	Cetuximab-Compound 25 linker	[43]
ADC Info	Cetuximab-Compound 31	Auristatin 0101	Microtubule (MT)	Cetuximab-Compound 31 linker	[43]
ADC Info	Cetuximab-Compound 36	Monomethyl auristatin E	Microtubule (MT)	Cetuximab-Compound 36 linker	[43]
ADC Info	Cetuximab-Compound 43	PBD dimer	Human Deoxyribonucleic acid (hDNA)	Cetuximab-Compound 43 linker	[43]
ADC Info	Cetuximab-Compound 49	PBD dimer	Human Deoxyribonucleic acid (hDNA)	Cetuximab-Compound 49 linker	[43]
ADC Info	Cetuximab-Compound 55	Mertansine DM1	Microtubule (MT)	Cetuximab-Compound 55 linker	[43]
ADC Info	Cetuximab-Compound 59	Mertansine DM4	Microtubule (MT)	Cetuximab-Compound 59 linker	[43]
ADC Info	Cetuximab-Compound 64	Monomethyl auristatin E	Microtubule (MT)	Cetuximab-Compound 64 linker	[43]
ADC Info	Cetuximab-Compound 69	Monomethyl auristatin E	Microtubule (MT)	Cetuximab-Compound 69 linker	[43]
ADC Info	Cetuximab-Compound 74	PBD dimer	Human Deoxyribonucleic acid (hDNA)	Cetuximab-Compound 74 linker	[43]
ADC Info	Cetuximab-Compound 75	Monomethyl auristatin E	Microtubule (MT)	Cetuximab-Compound 75 linker	[43]
ADC Info	Cetuximab-Compound 76	Monomethyl auristatin E	Microtubule (MT)	Cetuximab-Compound 76 linker	[43]
ADC Info	Cetuximab-Compound 77	Mertansine DM1	Microtubule (MT)	Cetuximab-Compound 77 linker	[43]
ADC Info	Cetuximab-Compound 78	Auristatin 0101	Microtubule (MT)	Cetuximab-Compound 78 linker	[43]
ADC Info	Cetuximab-Compound 79	Auristatin 0101	Microtubule (MT)	Cetuximab-Compound 79 linker	[43]
ADC Info	Cetuximab-Compound 80	Mertansine DM4	Microtubule (MT)	Cetuximab-Compound 80 linker	[43]
ADC Info	CN114917361A ADC-1	CN114917361A ADC-1 payload	Undisclosed	CN114917361A ADC-1 linker	[44]
ADC Info	CN114917361A ADC-6	CN114917361A ADC-6 payload	Undisclosed	CN114917361A ADC-6 linker	[44]
ADC Info	CN114917361A ADC-11	CN114917361A ADC-11 payload	Undisclosed	CN114917361A ADC-11 linker	[44]
ADC Info	CN114917361A ADC-13	CN114917361A ADC-13 payload	Undisclosed	CN114917361A ADC-13 linker	[44]
ADC Info	CN114917361A ADC-16	CN114917361A ADC-16 payload	Undisclosed	CN114917361A ADC-16 linker	[44]
ADC Info	CN114917361A ADC-19	CN114917361A ADC-19 payload	Undisclosed	CN114917361A ADC-19 linker	[44]
ADC Info	CN114917361A ADC-21	CN114917361A ADC-21 payload	Undisclosed	CN114917361A ADC-21 linker	[44]
ADC Info	CN114917361A ADC-25	CN114917361A ADC-25 payload	Undisclosed	CN114917361A ADC-25 linker	[44]
ADC Info	CN114917361A ADC-27	CN114917361A ADC-27 payload	Undisclosed	CN114917361A ADC-27 linker	[44]
ADC Info	CN114917361A ADC-30	CN114917361A ADC-30 payload	Undisclosed	CN114917361A ADC-30 linker	[44]
ADC Info	CN114917361A ADC-33	CN114917361A ADC-33 payload	Undisclosed	CN114917361A ADC-33 linker	[44]
ADC Info	CN114917361A ADC-36	CN114917361A ADC-36 payload	Undisclosed	CN114917361A ADC-36 linker	[44]
ADC Info	CN114917361A ADC-39	CN114917361A ADC-39 payload	Undisclosed	CN114917361A ADC-39 linker	[44]
ADC Info	CN114917361A ADC-41	CN114917361A ADC-41 payload	Undisclosed	CN114917361A ADC-41 linker	[44]
ADC Info	CN114917361A ADC-44	CN114917361A ADC-44 payload	Undisclosed	CN114917361A ADC-44 linker	[44]
ADC Info	CN114917361A ADC-47	CN114917361A ADC-47 payload	Undisclosed	CN114917361A ADC-47 linker	[44]
ADC Info	CN114917361A ADC-50	CN114917361A ADC-50 payload	Undisclosed	CN114917361A ADC-50 linker	[44]
ADC Info	CN114917361A ADC-55	CN114917361A ADC-55 payload	Undisclosed	CN114917361A ADC-55 linker	[44]
ADC Info	CN114917361A ADC-58	CN114917361A ADC-58 payload	Undisclosed	CN114917361A ADC-58 linker	[44]
ADC Info	CN114917361A ADC-61	CN114917361A ADC-61 payload	Undisclosed	CN114917361A ADC-61 linker	[44]
ADC Info	CN114917361A ADC-64	CN114917361A ADC-64 payload	Undisclosed	CN114917361A ADC-64 linker	[44]
ADC Info	CN114917361A ADC-67	CN114917361A ADC-67 payload	Undisclosed	CN114917361A ADC-67 linker	[44]
ADC Info	CN114917361A ADC-70	CN114917361A ADC-70 payload	Undisclosed	CN114917361A ADC-70 linker	[44]
ADC Info	CN114917361A ADC-73	CN114917361A ADC-73 payload	Undisclosed	CN114917361A ADC-73 linker	[44]
ADC Info	CN114917361A ADC-76	CN114917361A ADC-76 payload	Undisclosed	CN114917361A ADC-76 linker	[44]
ADC Info	CN114917361A ADC-79	CN114917361A ADC-79 payload	Undisclosed	CN114917361A ADC-79 linker	[44]
ADC Info	CN114917361A ADC-82	CN114917361A ADC-82 payload	Undisclosed	CN114917361A ADC-82 linker	[44]
ADC Info	Cetuximab based antibody-drug conjugate	Mertansine DM1	Microtubule (MT)	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[45]
ADC Info	AGCM-22	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Ala-PABC	[46]
ADC Info	39143910 ADC 40	Monomethyl auristatin E	Microtubule (MT)	1- (4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde) based linker	[47]
ADC Info	36924655 ADC 33	Monomethyl auristatin E	Microtubule (MT)	Undisclosed	[48]
ADC Info	Cet-CL2A-FL118 (12)	Undisclosed	Undisclosed	CL2A	[49]
ADC Info	Cetuximab-SNS-032 ADC	SNS-032	Undisclosed	Mal-Val-Ala-PAB	[50]
ADC Info	Dual-function antibody conjugate	Undisclosed	Undisclosed	Undisclosed	[51]
ADC Info	CMPXC	Chlorin e6 (Ce6)	Undisclosed	Mal-PX linker	[52]
ADC Info	Cetuximab based PROTAC (CPRO)	Undisclosed	Undisclosed	Undisclosed	[53]
ADC Info	Cet-C8Pt (IV)	Undisclosed	Undisclosed	Undisclosed	[54]
ADC Info	Cet-IRDye800CW (DAR2)	IRDye800CW	Undisclosed	Undisclosed	[55]
ADC Info	Cet-IRDye800CW (DAR7)	IRDye800CW	Undisclosed	Undisclosed	[55]
ADC Info	Cet-IRDye800CW (DAR11)	IRDye800CW	Undisclosed	Undisclosed	[55]
ADC Info	Cetuximab-IRDye800-AF647	IRDye800CW; AF647	Undisclosed	Undisclosed	[56]
ADC Info	JP7623413B2 ExampleADC60	Undisclosed	Undisclosed	Undisclosed	[57]
ADC Info	US12144865B2 1a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 2a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 4a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 5a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 6a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 7a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 8a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 10a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 11a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 12a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 13a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 14a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 15a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 16a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 17a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 18a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 19a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 21a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 22a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 23a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 24a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 25a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 26a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 27a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 28a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 29a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 30a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 35a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 36a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 37a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 38a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 39a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 40a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 41a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 42a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 43a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	US12144865B2 44a	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	Cex-50-5	CN112209990B+Cex-50-5+payload	Undisclosed	CN112209990B+Cex-50-5+Linker	[60]
ADC Info	Cex-59	CN112209990B+Cex-59+payload	Undisclosed	CN112209990B+Cex-59+Linker	[60]
ADC Info	Cex-70	CN112209990B+Cex-70+payload	Undisclosed	CN112209990B+Cex-70+Linker	[60]
ADC Info	EP4227309A4 ADC-19	undisclosed	Undisclosed	Undisclosed	[61]
ADC Info	EP4227309A4 ADC-20	undisclosed	Undisclosed	Undisclosed	[61]
ADC Info	Cetuximab-I-9-0.03	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-9-0.03 linker	[62]
ADC Info	Cetuximab-I-18-0.04	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-18-0.04 linker	[62]
ADC Info	Cetuximab-I-38-0.31	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-38-0.31 linker	[62]
ADC Info	Cetuximab-I-39-0.46	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-39-0.46 linker	[62]
ADC Info	Cetuximab-I-40-0.69	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-40-0.69 linker	[62]
ADC Info	Cetuximab-I-45-0.7	Cetuximab-I-45-0.7 payload	Undisclosed	Cetuximab-I-45-0.7 linker	[62]
ADC Info	AU2023279443A1 Example A3c	U-031	Microtubule (MT)	AU2023279443A1, Example A3, Linker	[63]
ADC Info	CN113943310A ADC-19	D-D3 payload	DNA topoisomerase I (TOP1)	CN113943310A, ADC-1, Linker	[64]
ADC Info	CN113943310A ADC-20	D-D7 payload	DNA topoisomerase I (TOP1)	CN113943310A, ADC-1, Linker	[64]
ADC Info	CN118873678A ADC-19	Undisclosed	Undisclosed	Undisclosed	[65]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Anti-EGFR ADC	3-aminophenyl-hemiasterlin	Undisclosed	DBCO Val Cit PABA linker	[59]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Cetux Fc/Fab-vc-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[21]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Cetuximab (LC)-2i	Monomethyl auristatin F	Microtubule (MT)	Cetuximab(LC)-2i linker	[66]
ADC Info	Cetuximab (LC)-3i	Monomethyl auristatin F	Microtubule (MT)	Cetuximab(LC)-3i linker	[66]
ADC Info	Cetuximab (LC)-4i	Monomethyl auristatin F	Microtubule (MT)	Cetuximab(LC)-4i linker	[66]
ADC Info	Cetuximab (LC)-6e	Monomethyl auristatin E	Microtubule (MT)	Cetuximab(LC)-6e linker	[66]
ADC Info	Cetuximab (LC)-amanitin	Alpha-amanitin	DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)	Cetuximab(LC)-amanitin linker	[66]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	ADC14-0810	Monomethyl auristatin F	Microtubule (MT)	ADC14-0810 linker	[66]
ADC Info	Cetuximab (LC) G7-CVIM-3i	Monomethyl auristatin F	Microtubule (MT)	Cetuximab(LC) G7-CVIM-3i linker	[66]
ADC Info	Cetuximab (LC) G7-CVIM-4i	Monomethyl auristatin F	Microtubule (MT)	Cetuximab(LC) G7-CVIM-4i linker	[66]
ADC Info	Cetuximab (LC) G7-CVIM-6e	Monomethyl auristatin E	Microtubule (MT)	Cetuximab(LC) G7-CVIM-6e linker	[66]
ADC Info	Cetuximab (LC) G7-CVIM-amanitin	Alpha-amanitin	DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)	Cetuximab(LC) G7-CVIM-amanitin linker	[66]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	LCB14-0645	Monomethyl auristatin F	Microtubule (MT)	LCB14-0645 linker	[66]
ADC Info	Cetuximab (LV) G7-CVIM-3i	Monomethyl auristatin F	Microtubule (MT)	Cetuximab(LV) G7-CVIM-3i linker	[66]
ADC Info	Cetuximab (LV) G7-CVIM-4i	Monomethyl auristatin F	Microtubule (MT)	Cetuximab(LV) G7-CVIM-4i linker	[66]
ADC Info	Cetuximab (LV) G7-CVIM-6e	Monomethyl auristatin E	Microtubule (MT)	Cetuximab(LV) G7-CVIM-6e linker	[66]
ADC Info	Cetuximab (LV) G7-CVIM-amanitin	Alpha-amanitin	DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)	Cetuximab(LV) G7-CVIM-amanitin linker	[66]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	C-Fab-MMAE	Monomethyl auristatin E	Microtubule (MT)	Gly3-Val-Cit-PABC	[7]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Cetux Fab-vc-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[21]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Demupitamab-ADC-Tb5-1	Demupitamab-ADC-Tb5-1 payload	Undisclosed	Demupitamab-ADC-Tb5-1 linker	[34]
ADC Info	Demupitamab-ADC-Tb5-2	Demupitamab-ADC-Tb5-2 payload	Undisclosed	Demupitamab-ADC-Tb5-2 linker	[34]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Depatuxizumab mafodotin	MMAF	Microtubule (MT)	Maleimido-caproyl
ADC Info	Depatuxizumab-ADC-Tb5-1	Depatuxizumab-ADC-Tb5-1 payload	Undisclosed	Depatuxizumab-ADC-Tb5-1 linker	[34]
ADC Info	Depatuxizumab-ADC-Tb5-2	Depatuxizumab-ADC-Tb5-2 payload	Undisclosed	Depatuxizumab-ADC-Tb5-2 linker	[34]
ADC Info	WO2017089890A1 ADC73	Monomethyl auristatin F	Microtubule (MT)	WO2017089890A1_ADC73 linker	[42]
ADC Info	WO2017089890A1 ADC74	Monomethyl auristatin E	Microtubule (MT)	WO2017089890A1_ADC74 linker	[42]
ADC Info	WO2017089890A1 ADC75	Monomethyl auristatin F	Microtubule (MT)	WO2017089890A1_ADC75 linker	[42]
ADC Info	JP7623413B2 ExampleADC57	Undisclosed	Undisclosed	Undisclosed	[57]
ADC Info	JP7623413B2 ExampleADC58	Undisclosed	Undisclosed	Undisclosed	[57]
ADC Info	JP7560255B2 ControlADC57	Undisclosed	Undisclosed	Undisclosed	[67]
ADC Info	JP7560255B2 ControlADC58	Undisclosed	Undisclosed	Undisclosed	[67]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	ABBV-322	PBD dimer	Human Deoxyribonucleic acid (hDNA)	Mc-Val-Ala	[68]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	RN765C	Auristatin 0101	Microtubule (MT)	AcLys-Val-Cit-PABC	[69]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	anti-EGFR Ab No.1 (L234A, L235A, L328C)-vcMMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[70]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	anti-EGFR Ab No.1 (L328C)-vcMMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[70]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	anti-EGFR Ab No.3 (L234A, L235A, L328C)-vcMMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[70]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Cotinine-duocarmycin	Duocarmycin Sa	Human Deoxyribonucleic acid (hDNA)	Mc-Val-Cit-PABC-DMAE	[71]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Fcab-1-MMAE	Monomethyl auristatin E	Microtubule (MT)	Gly3-Val-Cit-PABC	[7]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Fcab-2-MMAE	Monomethyl auristatin E	Microtubule (MT)	Gly3-Val-Cit-PABC	[7]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Fcab-3-MMAE	Monomethyl auristatin E	Microtubule (MT)	Gly3-Val-Cit-PABC	[7]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Futuximab-ADC-Tb5-1	Futuximab-ADC-Tb5-1 payload	Undisclosed	Futuximab-ADC-Tb5-1 linker	[34]
ADC Info	Futuximab-ADC-Tb5-2	Futuximab-ADC-Tb5-2 payload	Undisclosed	Futuximab-ADC-Tb5-2 linker	[34]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Fv-LDP-D3-AE	Lidamycin	Human Deoxyribonucleic acid (hDNA)	Undisclosed	[72]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Cetux Cys-vc-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[21]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Glyco-cetuximab Fab-vc-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[21]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Cetux Fc/Fab-vc-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[21]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Hu-Alpha-EGFR (ACVC)-172	IMSA172	Stimulator of interferon genes protein (STING1)	Mc-Val-Cit-PABC	[23]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Imgatuzumab-ADC-Tb5-1	Imgatuzumab-ADC-Tb5-1 payload	Undisclosed	Imgatuzumab-ADC-Tb5-1 linker	[34]
ADC Info	Imgatuzumab-ADC-Tb5-2	Imgatuzumab-ADC-Tb5-2 payload	Undisclosed	Imgatuzumab-ADC-Tb5-2 linker	[34]
ADC Info	AU2023226367A1-3c	Auristatin E	Microtubule (MT)	RU20241285-3-linker	[73]
ADC Info	CN119630431A ADC-94	CN119630431A-ADC-82-PAYLOAD	Undisclosed	CN119630431A-ADC-82-LINKER	[74]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Laprituximab emtansine	DM1	Microtubule (MT)	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
ADC Info	Laprituximab-ADC-Tb5-1	Laprituximab-ADC-Tb5-1 payload	Undisclosed	Laprituximab-ADC-Tb5-1 linker	[34]
ADC Info	Laprituximab-ADC-Tb5-2	Laprituximab-ADC-Tb5-2 payload	Undisclosed	Laprituximab-ADC-Tb5-2 linker	[34]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Losatuxizumab vedotin	MMAE	Microtubule (MT)	Mc-Val-Cit-PABC

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Losatuxzumab-ADC-Tb5-1	Losatuxzumab-ADC-Tb5-1 payload	Undisclosed	Losatuxzumab-ADC-Tb5-1 linker	[34]
ADC Info	Losatuxzumab-ADC-Tb5-2	Losatuxzumab-ADC-Tb5-2 payload	Undisclosed	Losatuxzumab-ADC-Tb5-2 linker	[34]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	LR004-Val-Cit-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[75]
ADC Info	LR-DM1	Mertansine DM1	Microtubule (MT)	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[76]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	AVID100	DM1	Microtubule (MT)	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Matuzumab-ADC-Tb5-1	Matuzumab-ADC-Tb5-1 payload	Undisclosed	Matuzumab-ADC-Tb5-1 linker	[34]
ADC Info	Matuzumab-ADC-Tb5-2	Matuzumab-ADC-Tb5-2 payload	Undisclosed	Matuzumab-ADC-Tb5-2 linker	[34]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Modotuximab-ADC-Tb5-1	Modotuximab-ADC-Tb5-1 payload	Undisclosed	Modotuximab-ADC-Tb5-1 linker	[34]
ADC Info	Modotuximab-ADC-Tb5-2	Modotuximab-ADC-Tb5-2 payload	Undisclosed	Modotuximab-ADC-Tb5-2 linker	[34]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Mu-Alpha-EGFR-172	IMSA172	Stimulator of interferon genes protein (STING1)	Mc-Val-Cit-PABC	[23]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	NC-6201	E7974	Microtubule (MT)	Undisclosed	[77]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Necitumumab-ADC-Tb5-1	Necitumumab-ADC-Tb5-1 payload	Undisclosed	Necitumumab-ADC-Tb5-1 linker	[34]
ADC Info	Necitumumab-ADC-Tb5-2	Necitumumab-ADC-Tb5-2 payload	Undisclosed	Necitumumab-ADC-Tb5-2 linker	[34]
ADC Info	WO2024055886A1 ADC1	Undisclosed	Undisclosed	Undisclosed	[78]
ADC Info	WO2024055886A1 ADC2	Undisclosed	Undisclosed	Undisclosed	[78]
ADC Info	WO2024055886A1 ADC3	Undisclosed	Undisclosed	Undisclosed	[78]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Nimotuzumab-ADC-24-1	Nimotuzumab-ADC-24-1 payload	Undisclosed	Nimotuzumab-ADC-24-1 linker	[79]
ADC Info	Nimotuzumab-ADC-24-2	Nimotuzumab-ADC-24-2 payload	Undisclosed	Nimotuzumab-ADC-24-2 linker	[79]
ADC Info	Nimotuzumab-ADC-24-3	Nimotuzumab-ADC-24-3 payload	Undisclosed	Nimotuzumab-ADC-24-3 linker	[79]
ADC Info	Nimotuzumab-ADC-24-4	Nimotuzumab-ADC-24-4 payload	Undisclosed	Nimotuzumab-ADC-24-4 linker	[79]
ADC Info	Nimotuzumab-ADC-24-5	Nimotuzumab-ADC-24-5 payload	Undisclosed	Nimotuzumab-ADC-24-5 linker	[79]
ADC Info	Nimotuzumab-ADC-24-6	Nimotuzumab-ADC-24-6 payload	Undisclosed	Nimotuzumab-ADC-24-6 linker	[79]
ADC Info	Nimotuzumab-ADC-24-7	Nimotuzumab-ADC-24-7 payload	Undisclosed	Nimotuzumab-ADC-24-7 linker	[79]
ADC Info	Nimotuzumab-ADC-24-8	Nimotuzumab-ADC-24-8 payload	Undisclosed	Nimotuzumab-ADC-24-8 linker	[79]
ADC Info	Nimotuzumab-ADC-24-9	Nimotuzumab-ADC-24-9 payload	Undisclosed	Nimotuzumab-ADC-24-9 linker	[79]
ADC Info	Nimotuzumab-ADC-24-10	Nimotuzumab-ADC-24-10 payload	Undisclosed	Nimotuzumab-ADC-24-10 linker	[79]
ADC Info	Nimotuzumab-ADC-24-11	Nimotuzumab-ADC-24-11 payload	Undisclosed	Nimotuzumab-ADC-24-11 linker	[79]
ADC Info	Nimotuzumab-ADC-24-12	Nimotuzumab-ADC-24-12 payload	Undisclosed	Nimotuzumab-ADC-24-12 linker	[79]
ADC Info	Nimotuzumab-ADC-24-13	Nimotuzumab-ADC-24-13 payload	Undisclosed	Nimotuzumab-ADC-24-13 linker	[79]
ADC Info	Nimotuzumab-ADC-Tb5-1	Nimotuzumab-ADC-Tb5-1 payload	Undisclosed	Nimotuzumab-ADC-Tb5-1 linker	[34]
ADC Info	Nimotuzumab-ADC-Tb5-2	Nimotuzumab-ADC-Tb5-2 payload	Undisclosed	Nimotuzumab-ADC-Tb5-2 linker	[34]
ADC Info	Nimotuzumab-Compound 9	Mertansine DM1	Microtubule (MT)	Nimotuzumab-Compound 9 linker	[43]
ADC Info	Nimotuzumab-Compound 17	Mertansine DM4	Microtubule (MT)	Nimotuzumab-Compound 17 linker	[43]
ADC Info	Nimotuzumab-Compound 25	Monomethyl auristatin E	Microtubule (MT)	Nimotuzumab-Compound 25 linker	[43]
ADC Info	Nimotuzumab-Compound 31	Auristatin 0101	Microtubule (MT)	Nimotuzumab-Compound 31 linker	[43]
ADC Info	Nimotuzumab-Compound 36	Monomethyl auristatin E	Microtubule (MT)	Nimotuzumab-Compound 36 linker	[43]
ADC Info	Nimotuzumab-Compound 43	PBD dimer	Human Deoxyribonucleic acid (hDNA)	Nimotuzumab-Compound 43 linker	[43]
ADC Info	Nimotuzumab-Compound 49	PBD dimer	Human Deoxyribonucleic acid (hDNA)	Nimotuzumab-Compound 49 linker	[43]
ADC Info	Nimotuzumab-Compound 55	Mertansine DM1	Microtubule (MT)	Nimotuzumab-Compound 55 linker	[43]
ADC Info	Nimotuzumab-Compound 59	Mertansine DM4	Microtubule (MT)	Nimotuzumab-Compound 59 linker	[43]
ADC Info	Nimotuzumab-Compound 64	Monomethyl auristatin E	Microtubule (MT)	Nimotuzumab-Compound 64 linker	[43]
ADC Info	Nimotuzumab-Compound 69	Monomethyl auristatin E	Microtubule (MT)	Nimotuzumab-Compound 69 linker	[43]
ADC Info	Nimotuzumab-Compound 74	PBD dimer	Human Deoxyribonucleic acid (hDNA)	Nimotuzumab-Compound 74 linker	[43]
ADC Info	Nimotuzumab-Compound 75	Monomethyl auristatin E	Microtubule (MT)	Nimotuzumab-Compound 75 linker	[43]
ADC Info	Nimotuzumab-Compound 76	Monomethyl auristatin E	Microtubule (MT)	Nimotuzumab-Compound 76 linker	[43]
ADC Info	Nimotuzumab-Compound 77	Mertansine DM1	Microtubule (MT)	Nimotuzumab-Compound 77 linker	[43]
ADC Info	Nimotuzumab-Compound 78	Auristatin 0101	Microtubule (MT)	Nimotuzumab-Compound 78 linker	[43]
ADC Info	Nimotuzumab-Compound 79	Auristatin 0101	Microtubule (MT)	Nimotuzumab-Compound 79 linker	[43]
ADC Info	Nimotuzumab-Compound 80	Mertansine DM4	Microtubule (MT)	Nimotuzumab-Compound 80 linker	[43]
ADC Info	CN114917361A ADC-3	CN114917361A ADC-3 payload	Undisclosed	CN114917361A ADC-3 linker	[44]
ADC Info	Nim-CL2A-FL118 (13)	Undisclosed	Undisclosed	CL2A	[49]
ADC Info	US12144865B2 1i	Undisclosed	Undisclosed	Undisclosed	[58]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	DXC-004A	Tubulysin B analog	Microtubule (MT)	Undisclosed
ADC Info	DXC004	Tubulysin B analog	Microtubule (MT)	Undisclosed	[80]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	CyEt-Pan-Duo	DEAEA duocarmycin	Human Deoxyribonucleic acid (hDNA)	Mal-PEG4-Triazol-Cyanine cage	[81]
ADC Info	AVID-300	Mertansine DM1	Microtubule (MT)	Undisclosed	[82]
ADC Info	Panitumumab-DNA conjugate	DNA mimics	Human Deoxyribonucleic acid (hDNA)	Undisclosed	[33]
ADC Info	Panitumumab-ADC-Tb5-1	Panitumumab-ADC-Tb5-1 payload	Undisclosed	Panitumumab-ADC-Tb5-1 linker	[34]
ADC Info	Panitumumab-ADC-Tb5-2	Panitumumab-ADC-Tb5-2 payload	Undisclosed	Panitumumab-ADC-Tb5-2 linker	[34]
ADC Info	Panitumumab-Compound 9	Mertansine DM1	Microtubule (MT)	Panitumumab-Compound 9 linker	[43]
ADC Info	Panitumumab-Compound 17	Mertansine DM4	Microtubule (MT)	Panitumumab-Compound 17 linker	[43]
ADC Info	Panitumumab-Compound 25	Monomethyl auristatin E	Microtubule (MT)	Panitumumab-Compound 25 linker	[43]
ADC Info	Panitumumab-Compound 31	Auristatin 0101	Microtubule (MT)	Panitumumab-Compound 31 linker	[43]
ADC Info	Panitumumab-Compound 36	Monomethyl auristatin E	Microtubule (MT)	Panitumumab-Compound 36 linker	[43]
ADC Info	Panitumumab-Compound 43	PBD dimer	Human Deoxyribonucleic acid (hDNA)	Panitumumab-Compound 43 linker	[43]
ADC Info	Panitumumab-Compound 49	PBD dimer	Human Deoxyribonucleic acid (hDNA)	Panitumumab-Compound 49 linker	[43]
ADC Info	Panitumumab-Compound 55	Mertansine DM1	Microtubule (MT)	Panitumumab-Compound 55 linker	[43]
ADC Info	Panitumumab-Compound 59	Mertansine DM4	Microtubule (MT)	Panitumumab-Compound 59 linker	[43]
ADC Info	Panitumumab-Compound 64	Monomethyl auristatin E	Microtubule (MT)	Panitumumab-Compound 64 linker	[43]
ADC Info	Panitumumab-Compound 69	Monomethyl auristatin E	Microtubule (MT)	Panitumumab-Compound 69 linker	[43]
ADC Info	Panitumumab-Compound 74	PBD dimer	Human Deoxyribonucleic acid (hDNA)	Panitumumab-Compound 74 linker	[43]
ADC Info	Panitumumab-Compound 75	Monomethyl auristatin E	Microtubule (MT)	Panitumumab-Compound 75 linker	[43]
ADC Info	Panitumumab-Compound 76	Monomethyl auristatin E	Microtubule (MT)	Panitumumab-Compound 76 linker	[43]
ADC Info	Panitumumab-Compound 77	Mertansine DM1	Microtubule (MT)	Panitumumab-Compound 77 linker	[43]
ADC Info	Panitumumab-Compound 78	Auristatin 0101	Microtubule (MT)	Panitumumab-Compound 78 linker	[43]
ADC Info	Panitumumab-Compound 79	Auristatin 0101	Microtubule (MT)	Panitumumab-Compound 79 linker	[43]
ADC Info	Panitumumab-Compound 80	Mertansine DM4	Microtubule (MT)	Panitumumab-Compound 80 linker	[43]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Pimurutamab-ADC-Tb5-1	Pimurutamab-ADC-Tb5-1 payload	Undisclosed	Pimurutamab-ADC-Tb5-1 linker	[34]
ADC Info	Pimurutamab-ADC-Tb5-2	Pimurutamab-ADC-Tb5-2 payload	Undisclosed	Pimurutamab-ADC-Tb5-2 linker	[34]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	RC68-PY-Val-Cit-PABC-MMAE	Monomethyl auristatin E	Microtubule (MT)	PY-VC-PABC	[83]
ADC Info	RC68-Mc-Val-Cit-PABC-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[83]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	SCT-200-M-1	Monomethyl auristatin E	Microtubule (MT)	CN112604004B-SCT-200-M-1-linker	[84]
ADC Info	SCT-200-M-2	Monomethyl auristatin E	Microtubule (MT)	CN112604004B-SCT-200-M-2-linker	[84]
ADC Info	SCT-200-M-3	Monomethyl auristatin E	Microtubule (MT)	CN112604004B-SCT-200-M-3-linker	[84]
ADC Info	SCT-200-C-1	Monomethyl auristatin E	Microtubule (MT)	CN112604004B-SCT-200-C-1-linker	[84]
ADC Info	SCT-200-C-2	Monomethyl auristatin E	Microtubule (MT)	CN112604004B-SCT-200-C-2-linker	[84]
ADC Info	SCT-200-C-3	Monomethyl auristatin E	Microtubule (MT)	CN112604004B-SCT-200-C-3-linker	[84]
ADC Info	SCT-200-C-4	Monomethyl auristatin E	Microtubule (MT)	CN112604004B-SCT-200-C-4-linker	[84]
ADC Info	SCT-200-C-5	Monomethyl auristatin E	Microtubule (MT)	CN112604004B-SCT-200-C-5-linker	[84]
ADC Info	SCT-200-R-1	Monomethyl auristatin E	Microtubule (MT)	CN112604004B-SCT-200-R-1-linker	[84]
ADC Info	SCT-200-R-2	Monomethyl auristatin E	Microtubule (MT)	CN112604004B-SCT-200-R-2-linker	[84]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Serclutamab talirine	SGD-1882	Human deoxyribonucleic acid (hDNA)	Mc-Val-Ala
ADC Info	Serclutamab-ADC-Tb5-1	Serclutamab-ADC-Tb5-1 payload	Undisclosed	Serclutamab-ADC-Tb5-1 linker	[34]
ADC Info	Serclutamab-ADC-Tb5-2	Serclutamab-ADC-Tb5-2 payload	Undisclosed	Serclutamab-ADC-Tb5-2 linker	[34]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	SWY2110-JSSW-001 ADC	Exatecan	DNA topoisomerase 1 (TOP1)	C12-1 linker	[85]
ADC Info	SWY2110-GGFG-DXD ADC	DX-8951 derivative (DXd)	DNA topoisomerase 1 (TOP1)	Mc-Gly-Gly-Phe-Gly	[85]
ADC Info	SWY2110-VC-MMAE ADC	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[85]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	SWY2111-JSSW-001 ADC	Exatecan	DNA topoisomerase 1 (TOP1)	C12-1 linker	[85]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	SWY2112-JSSW-001 ADC	Exatecan	DNA topoisomerase 1 (TOP1)	C12-1 linker	[85]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	SWY2113-JSSW-001 ADC	Exatecan	DNA topoisomerase 1 (TOP1)	C12-1 linker	[85]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Tomuzotuximab-ADC-Tb5-1	Tomuzotuximab-ADC-Tb5-1 payload	Undisclosed	Tomuzotuximab-ADC-Tb5-1 linker	[34]
ADC Info	Tomuzotuximab-ADC-Tb5-2	Tomuzotuximab-ADC-Tb5-2 payload	Undisclosed	Tomuzotuximab-ADC-Tb5-2 linker	[34]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Zalutumumab-ADC-Tb5-1	Zalutumumab-ADC-Tb5-1 payload	Undisclosed	Zalutumumab-ADC-Tb5-1 linker	[34]
ADC Info	Zalutumumab-ADC-Tb5-2	Zalutumumab-ADC-Tb5-2 payload	Undisclosed	Zalutumumab-ADC-Tb5-2 linker	[34]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	HTI-1511	Undisclosed	Undisclosed	Undisclosed	[86]
ADC Info	Probody drug conjugate (CytomX Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[87]
ADC Info	Recombinant humanized anti-EGFR mAb-DUO-5 conjugate	Duostatin 5	Human Deoxyribonucleic acid (hDNA)	Undisclosed	[88]
ADC Info	PBX-003	Undisclosed	Undisclosed	Undisclosed	[89]
ADC Info	NS Cys-vc-MMAE	Monomethyl auristatin E	Microtubule (MT)	Mc-Val-Cit-PABC	[21]
ADC Info	STI-A020X	Undisclosed	Undisclosed	Undisclosed	[90]
ADC Info	EGFR-EDV-RRM1	Doxorubicin	DNA topoisomerase 2-alpha (TOP2A)	Undisclosed	[91]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	WO2024043319A1 82	Undisclosed	Undisclosed	Undisclosed	[92]
ADC Info	CN107614020A 1MB-701	Undisclosed	Undisclosed	Undisclosed	[93]
ADC Info	CN107614020A 1MB-702	Undisclosed	Undisclosed	Undisclosed	[93]
ADC Info	CN114786729A ADC-VII	CDN-A	Undisclosed	Undisclosed	[94]
ADC Info	CN114786729A ADC-VIII	CDN-A	Undisclosed	Undisclosed	[94]
ADC Info	CN114786729A ADC-IX	CDN-A	Undisclosed	Undisclosed	[94]
ADC Info	CN114786729A ADC-X	CDN-A	Undisclosed	Undisclosed	[94]
ADC Info	CN114786729A ADC-XI	CDN-A	Undisclosed	Undisclosed	[94]
ADC Info	CN117731799A ADC-1	CN117731799A-ADC-1-payload	Undisclosed	CN117731799A-ADC-1-linker	[95]
ADC Info	CN115429890B ADC-1	Active metabolite of irinotecan SN38	DNA topoisomerase 1 (TOP1)	DBCO-PEG8-glu	[96]
ADC Info	CN115429890B ADC-2	Active metabolite of irinotecan SN38	DNA topoisomerase 1 (TOP1)	DBCO-Val-Cit-PABC	[96]

Ref 1	Click Chemistry-Generated Auristatin F-Linker-Benzylguanine for a SNAP-Tag-Based Recombinant Antibody-Drug Conjugate Demonstrating Selective Cytotoxicity toward EGFR-Overexpressing Tumor Cells. ACS Omega. 2023 Jan 17;8(4):4026-4037. doi: 10.1021/acsomega.2c06844. eCollection 2023 Jan 31.
Ref 2	RAFT Polymer-Antibody Conjugation: Squaramide Ester Chemistry Leads to Conjugates with a Therapeutic Anti-EGFR Antibody with Full Retention of Activity and Increased Tumor Uptake In Vivo
Ref 3	Antibody-drug conjugates (A2DCs) with enzymatically cleavable groups
Ref 4	A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models. Signal Transduct Target Ther. 2021 Sep 3;6(1):320. doi: 10.1038/s41392-021-00666-5.
Ref 5	Anti-EGFR antibodies, antibody-drug conjugates, pharmaceutical compositions and uses for treating cancer and inhibiting or reducing solid tumor growth
Ref 6	Anti-egfr antibodies and antibody drug conjugates.
Ref 7	EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing. Biol Chem. 2021 Sep 20;403(5-6):525-534.
Ref 8	Novel tryptophan-based antibody-drug conjugate (ADC) targeting EGFR-positive lung cancer demonstrates robust antitumor efficacy by triggering immunogenic cell death
Ref 9	Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy. Eng Life Sci. 2020 Oct 7;21(1-2):37-44. doi: 10.1002/elsc.202000027. eCollection 2021 Jan.
Ref 10	Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers. Mol Pharm. 2019 Dec 2;16(12):4817-4825. doi: 10.1021/acs.molpharmaceut.9b00696. Epub 2019 Oct 29.
Ref 11	Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs). ACS Med Chem Lett. 2019 Jul 22;10(8):1211-1215. doi: 10.1021/acsmedchemlett.9b00254. eCollection 2019 Aug 8.
Ref 12	Conjugates and antibody-drug conjugates prepared therefrom
Ref 13	Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity. Biomed Pharmacother. 2023 Jan;157:114047.
Ref 14	Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies. Mol Cancer Ther. 2019 Jun;18(6):1104-1114. doi: 10.1158/1535-7163.MCT-18-0854.
Ref 15	Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C. Biochem Biophys Res Commun. 2006 Oct 20;349(2):816-24. doi: 10.1016/j.bbrc.2006.08.114. Epub 2006 Aug 28.
Ref 16	Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. Oncotarget. 2019 Feb 1;10(10):1031-1044. doi: 10.18632/oncotarget.26613. eCollection 2019 Feb 1.
Ref 17	A camptothecin drug and its antibody conjugate thereof
Ref 18	Antibody-drug conjugate; 2016-08-25.
Ref 19	A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
Ref 20	Antibody-drug conjugates containing two different drugs
Ref 21	MAbs. 2023 Jan-Dec;15(1):2149057. doi: 10.1080/19420862.2022.2149057.
Ref 22	A new class of DNA sequence-selective G-A cross-linking antibody-drug conjugate (ADC) payloads. Cancer Res (2022) 82 (12_Supplement): 1749.
Ref 23	Tumor-targeted delivery of a STING agonist improvescancer immunotherapy. Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2214278119.
Ref 24	Conjugation of Cetuximab - Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines. Asian Pac J Cancer Prev. 2022 May 1;23(5):1803-1812.
Ref 25	An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. Cancer Lett. 2023 Feb 1;554:216024.
Ref 26	Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release. Bioconjug Chem. 2022 Aug 17;33(8):1474-1484.
Ref 27	Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab. J Immunother Cancer. 2022 Dec;10(12):e005660.
Ref 28	EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy. Int J Nanomedicine. 2021 Mar 26;16:2443-2459. doi: 10.2147/IJN.S289228. eCollection 2021.
Ref 29	Compounds, linker-drugs and ligand-drug conjugates; 2020-06-16
Ref 30	A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells. Toxins (Basel). 2023 Jan 9;15(1):57. doi: 10.3390/toxins15010057.
Ref 31	Development of a new minimally invasive phototherapy for lung cancer using antibody-toxin conjugate. Thorac Cancer. 2023 Mar;14(7):645-653. doi: 10.1111/1759-7714.14776. Epub 2023 Jan 19.
Ref 32	Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II. Mol Ther Oncolytics. 2020 Jul 6;18:304-316. doi: 10.1016/j.omto.2020.07.001. eCollection 2020 Sep 25.
Ref 33	Aptamer-Directed Conjugation of DNA to Therapeutic Antibodies. Bioconjug Chem. 2019 Aug 21;30(8):2127-2135. doi: 10.1021/acs.bioconjchem.9b00363. Epub 2019 Jul 12.
Ref 34	Bioactive substance conjugate, preparation method therefor and use thereof; 2022-08-18.
Ref 35	Neodegrader conjugates; 2021-10-07.
Ref 36	Antibody-drug conjugates comprising branched linkers and methods related thereto; 2017-06-01.
Ref 37	Camptothecin derivative and ligand-drug conjugate thereof; 2022-04-21.
Ref 38	Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility. Antibodies (Basel). 2018 Mar 22;7(2):15. doi: 10.3390/antib7020015.
Ref 39	Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) c-MET Antibodies and Antibody-Drug Conjugates. J Biol Chem. 2016 Nov 25;291(48):25106-25119. doi: 10.1074/jbc.M116.753491. Epub 2016 Sep 30.
Ref 40	Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. Br J Cancer. 2020 Nov;123(10):1502-1512. doi: 10.1038/s41416-020-01046-6. Epub 2020 Sep 11.
Ref 41	Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates. Bioorg Med Chem. 2020 Dec 1;28(23):115793. doi: 10.1016/j.bmc.2020.115793. Epub 2020 Oct 6.
Ref 42	Conjugates comprising self-immolative groups and methods related thereto.
Ref 43	Covalent linkers in antibody-drug conjugates and methods of making and using the same.
Ref 44	Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen.
Ref 45	Introduction to basic information on ADC drug ADC-W-2589.
Ref 46	AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy
Ref 47	Use of a Cyclic α-Alkylidene-β-Diketone as a Cleavable Linker Strategy for Antibody-Drug Conjugates
Ref 48	Phenyldivinylsulfonamides for the construction of antibody-drug conjugates with controlled four payloads
Ref 49	Design, synthesis and biological evaluation of camptothecin analogue FL118 as a payload for antibody-drug conjugates in targeted cancer therapy
Ref 50	Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth
Ref 51	Dual-Function Antibody Conjugate-Enabled Photoimmunotherapy Complements Fluorescence and Photoacoustic Imaging of Head and Neck Cancer Spheroids
Ref 52	Synergistic Approach of Antibody-Photosensitizer Conjugate Independent of KRAS-Mutation and Its Downstream Blockade Pathway in Colorectal Cancer
Ref 53	Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations
Ref 54	Antibody-platinum (IV) prodrugs conjugates for targeted treatment of cutaneous squamous cell carcinoma
Ref 55	Increasing the Dye Payload of Cetuximab-IRDye800CW Enables Photodynamic Therapy
Ref 56	Temporal dynamics of fluorescence and photoacoustic signals of a Cetuximab-IRDye800 conjugate in EGFR-overexpressing tumors
Ref 57	Antibody-drug complexes containing hemiasterlin derivatives
Ref 58	Antibody drug conjugates with enzymatically cleavable groups
Ref 59	Bispecific antibody-drug conjugates targeting EGFR and MUC1 and uses thereof
Ref 60	Combreta-statin derivatives and their antibody-drug conjugates
Ref 61	Deuterated camptothecin derivatives and antibody-drug conjugates thereof
Ref 62	Directed conjugation technology
Ref 63	Antibody-multidrug conjugate
Ref 64	Deuterated camptothecin derivatives and their antibody-drug conjugates
Ref 65	Antibody-drug conjugates and uses thereof
Ref 66	Compositions and methods related to anti-egfr antibody drug conjugates; 2017-03-30.
Ref 67	Pharmaceuticals containing antibody-drug complexes containing hemiasterin derivatives
Ref 68	Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. Pharmaceuticals (Basel). 2020 Oct 2;13(10):289. doi: 10.3390/ph13100289.
Ref 69	RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models. Oncotarget. 2018 Sep 11;9(71):33446-33458. doi: 10.18632/oncotarget.26002. eCollection 2018 Sep 11.
Ref 70	Antibody compositions comprising Fc mutations and site-specific conjugation properties for use in treating cancer, immunological disorders, and methods thereof
Ref 71	Bispecific anti-mPDGFR x cotinine scFv-C()-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFR expressing cells. Methods. 2019 Feb 1;154:125-135. doi: 10.1016/j.ymeth.2018.10.002. Epub 2018 Oct 4.
Ref 72	A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer. Drug Deliv. 2022 Dec;29(1):1243-1256.
Ref 73	Antibody-drug conjugate
Ref 74	Antibody-drug conjugates
Ref 75	Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer. Mil Med Res. 2021 Dec 9;8(1):63.
Ref 76	Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer. J Med Chem. 2022 May 26;65(10):7141-7153. doi: 10.1021/acs.jmedchem.1c01920. Epub 2022 May 6.
Ref 77	Preclinical evaluation of NC-6201, an antibody/drug-conjugated micelle incorporating novel hemiasterlin analogue E7974.
Ref 78	Branched polyethylene glycol linkers and their uses
Ref 79	Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof; 2020-04-02.
Ref 80	DAC biotechnology company product pipeline
Ref 81	In Vivo Activation of Duocarmycin-Antibody Conjugates by Near-Infrared Light. ACS Cent Sci. 2017 Apr 26;3(4):329-337. doi: 10.1021/acscentsci.7b00026. Epub 2017 Feb 24.
Ref 82	ADC review AVID-300
Ref 83	Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 2019 Jul;84(1):61-72. doi: 10.1007/s00280-019-03848-9. Epub 2019 Apr 29.
Ref 84	Anti-human EGFR antibody-drug conjugates and their preparation methods and applications
Ref 85	Uses of an antibody-drug conjugate
Ref 86	Preclinical evaluation of a next-generation, EGFR targeting ADC that promotes regression in KRAS or BRAF mutant tumors. Cancer Res (2016) 76 (14_Supplement): 1217.
Ref 87	Introduction to basic information on ADC drug Probody drug conjugate (CytomX Therapeutics)
Ref 88	Introduction to basic information on recombinant humanized anti-EGFR mAb-DUO-5 conjugate(Zova Biotherapeutics/Zhejiang Hisun Pharmaceutical).
Ref 89	Pinotbio biotechnology company product pipeline
Ref 90	Sorrento therapeutics next-generation cancer therapeutics; November 2013
Ref 91	Introduction to basic information on antibody-drug nanocell conjugates(EnGeneIC Pty Ltd.).
Ref 92	Antibody-drug complexes
Ref 93	Conjugates targeting intracellular tumor-associated antigens for treatment of cancer
Ref 94	Antibody-STING agonist conjugates and their use in immunotherapy
Ref 95	An antibody-drug conjugate formulation and its preparation process
Ref 96	Conjugates and antibody-drug conjugates prepared therefrom